Therapeutic alternatives for colchicine-resistant FMF: the CLUSTER study

Raffaele Manna; Mg Massaro; Donato Rigante; Ll Sicignano; E Verrecchia

Therapeutic alternatives for colchicine-resistant FMF: the CLUSTER study

Raffaele Manna, Mg Massaro, Donato Rigante, Ll Sicignano, E Verrecchia

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Abstract

The Cluster trial introduced an innovative study design to reinforce the hypothesis, already demonstrated by minor studies, of the efficacy of canakinumab, a specific anti-IL-1 drug, in IL-1-mediated autoinflammatory diseases such as FMF.

Lingua originale	English
pagine (da-a)	8-11
Numero di pagine	4
Rivista	FOCUS ON AUTOINFLAMMATORY DISORDERS
Volume	2020
Stato di pubblicazione	Pubblicato - 2020

Keywords

Autoinflammation
Familial Mediterranean fever

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{7730e31c046e4687b2aaa32216b6b940,

title = "Therapeutic alternatives for colchicine-resistant FMF: the CLUSTER study",

abstract = "The Cluster trial introduced an innovative study design to reinforce the hypothesis, already demonstrated by minor studies, of the efficacy of canakinumab, a specific anti-IL-1 drug, in IL-1-mediated autoinflammatory diseases such as FMF.",

keywords = "Autoinflammation, Familial Mediterranean fever, Autoinflammation, Familial Mediterranean fever",

author = "Raffaele Manna and Mg Massaro and Donato Rigante and Ll Sicignano and E Verrecchia",

year = "2020",

language = "English",

volume = "2020",

pages = "8--11",

journal = "FOCUS ON AUTOINFLAMMATORY DISORDERS",

issn = "2420-9309",

publisher = "Alter marketing & pubblicit{\`a}",

}

TY - JOUR

T1 - Therapeutic alternatives for colchicine-resistant FMF: the CLUSTER study

AU - Manna, Raffaele

AU - Massaro, Mg

AU - Rigante, Donato

AU - Sicignano, Ll

AU - Verrecchia, E

PY - 2020

Y1 - 2020

N2 - The Cluster trial introduced an innovative study design to reinforce the hypothesis, already demonstrated by minor studies, of the efficacy of canakinumab, a specific anti-IL-1 drug, in IL-1-mediated autoinflammatory diseases such as FMF.

AB - The Cluster trial introduced an innovative study design to reinforce the hypothesis, already demonstrated by minor studies, of the efficacy of canakinumab, a specific anti-IL-1 drug, in IL-1-mediated autoinflammatory diseases such as FMF.

KW - Autoinflammation

KW - Familial Mediterranean fever

KW - Autoinflammation

KW - Familial Mediterranean fever

UR - http://hdl.handle.net/10807/153113

M3 - Article

SN - 2420-9309

VL - 2020

SP - 8

EP - 11

JO - FOCUS ON AUTOINFLAMMATORY DISORDERS

JF - FOCUS ON AUTOINFLAMMATORY DISORDERS

ER -

Therapeutic alternatives for colchicine-resistant FMF: the CLUSTER study

Abstract

Keywords

Altri file e collegamenti

Fingerprint

Cita questo